Redeye briefly comments on Cinclus’ announcement that the first patient has been dosed in its pivota...
Redeye shares its view on Sleep Cycle ahead of the Q3 report due on 24 October.
Xplora's monthly subscriptions update shows that the Xplora Kids subscriber base for Q3 2025 amounte...
Redeye briefly comments on Guard Therapeutics announcing additional encouraging data from its comple...
Redeye comments on Physitrack ahead of its Q3 results, due on 21 October (rescheduled from 31 Octobe...
Redeye updates its estimates and valuation after Mendus’ clinical strategy update.
In a preliminary release ahead of its full report on 24 October 2025, AVTECH announced Q3 2025 net s...
Redeye is positive about Corline’s and Kardium’s development with a new ten-year agreement, and that...
Redeye comments on the termination of “Project Baxter”, which we believe was the right decision give...
Redeye is optimistic after Hansa’s directed share issue tonight, which was expanded from USD60m to U...
Redeye retains its SEK394 Base Case in Lime, leaving notable upside potential given the recent soft ...
Redeye provides a short comment on the recently announced Q3 sales figure from Scandinavian ChemoTec...
* Report out on 17 October * Q3e sales SEK 48m, EBIT SEK -0.
Redeye is positive about Corline’s new licensing and supply agreement with Kardium, which underlines...
* Byggmästaren proposes extraordinary dividend and share split * Updates dividend policy and reaffir...
